1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

Competitor Analysis: Therapeutic Antibodies 2015: Biosimilars & Biosuperiors

This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015.

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.

The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:

- VEGF
- TNF
- Her2
- CD20
- EGF-R
- B7.1/B7.2 (CD80/CD86)
- IL-6R
- Alpha4/beta1/7 integrin
- IgE
- RSV
- RANKL
- Complement C5
- IL-12/IL-23
- CD52


Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars and Biosuperiors
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars and Biosuperiors
Table of Contents
1)         2014 Sales of Therapeutic Antibodies
•          Anti-TNF Antibody Sales 2014
•          Cancer Antibody Sales 2014
•          Other Anti-Inflammatory Antibody Sales 2014
•          Ophthalmic Antibody Sales 2014
•          Cardiometabolic and Antiviral Antibody Sales 2014
2)         VEGF Antibodies
Marketed VEGF and VEGF-R Antibodies in Oncology:
•          Avastin Sales and Pipeline
•          Zaltrap Sales and Pipeline
•          Cyramza Sales and Pipeline
Avastin and Zaltrap Biosuperiors:
•          Anti-VEGF and Antibody Combination Pipeline
•          Bispecific Anti-VEGF Antibody Pipeline
Cyramza Biosuperiors:
•          Anti-VEGF-R and Antibody Combination Pipeline
•          Bispecific Anti-VEGF-R Antibody Pipeline
Avastin Biosimilar Pipeline:
Marketed VEGF Antibodies in Ophthalmology:
•          Lucentis Sales and Pipeline
•          Eylea Sales and Pipeline
Biosuperior Lucentis and Eylea Pipeline:
•          Anti-VEGF Pipeline in Ophthalmology
•          Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
Lucentis Biosimilar Pipeline
3)         TNF Antibodies
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
-           Humira Sales and Pipeline
-           Remicade Sales and Pipeline
-           Enbrel Sales and Pipeline
-           Simponi Sales and Pipeline
-           Cimzia Sales and Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
-           Humira Biosimilar Antibody Pipeline
-           Remicade Biosimilar Antibody Pipeline
-           Enbrel Biosimilar Antibody Pipeline
-           Cimzia Biosimilar Antibody Pipeline
4)         Her2 Antibodies
Marketed Her2 Antibodies
-           Herceptin Sales and Pipeline
-           Perjeta Sales and Pipeline
-           Kadcyla Sales and Pipeline
Trastuzumab Biosuperiors
-           Engineered Her2 Antibodies
-           Bi- and Multispecific Her2 Antibodies
-           Her2 Antibody-Drug Conjugates
-           Other Her2 Antibodies
Herceptin Biosimilars
5)         CD20 Antibodies
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies and Sales
-           Rituxan/MabThera Pipeline and Sales
-           Gazyva/ Gazyvaro Pipeline and Sales
-           Arzerra Pipeline and Sales
-           Zevalin Pipeline and Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
-           Rituxan/MabThera (rituximab) Biosimilars
6)         EGF-R Antibodies
2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
-           Erbitux Sales and Pipeline
-           Vectibix Sales and Pipeline
-           Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
-           Engineered EGF-R Antibodies
-           Bi- and Multispecific EGF-R Antibodies
-           EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
-           Cetuximab Biosimilars
7)         RANKL Antibodies
Marketed RANKL Antibodies
-           Prolia Sales and Pipeline
-           XGEVA Sales and Pipeline
-           Ranmark/Pralia Pipeline
Biosuperior RANKL Antibodies
Biosimilar RANKL Antibodies
8)         Complement C5 Antibodies
Marketed C5 Antibody Sales and Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies
9)         Interleukin-12/-23 Antibodies
Marketed IL-12/-23 Antibody Sales and Pipeline
10)       Alpha4/Beta1/7 Antibodies
Marketed alpha4/beta1/7 Antibody Sales and Pipeline
11)       IgE Antibodies
Marketed IgE Antibody Sales and Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies
12)       CD80/86 (B7-1/B7-2) Antibodies
Marketed CD80/86 Antibodies Sales and Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies
13)       Interleukin-6 Receptor (IL-6R) Antibodies
Marketed IL-6R Antibody Sales and Pipeline
Biosuperior IL-6R Antibodies
Biosimilar IL-6R Antibodies
14)       Respiratory Syncytial Virus (RSV) Antibodies
Marketed RSV Antibody Sales
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies
15)       CD52 Antibodies
Marketed CD52 Antibody Sales
Biosuperor CD52 Antibodies
Biosimilar CD52 Antibodies
Corporate Therapeutic Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.